

Conference Cochairs:

Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, New York
Anirban Maitra, The University of Texas MD Anderson Cancer Center, Houston, Texas
Rosalie C. Sears, Oregon Health & Science University, Portland, Oregon
Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina

WEDNESDAY, SEPTEMBER 27

3:00 p.m.-8:30 p.m.

Registration Opens

America Ballroom Foyer

5:45 p.m.-7:30 p.m.

Welcome and Keynote Lectures

America North and Central Ballroom

5:45 p.m.-5:55 p.m.

Welcome from Cochairs

Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina

5:55 p.m.-6:00 p.m.

Welcome from Lead Supporter

Andrew Rakeman, Lustgarten Foundation, Woodbury, New York

6:00 p.m.-6:30 p.m.

Rising Star Keynote [CME Eligible]

“RNA switches” in pancreatic cancer: Expression, splicing and RNA-based therapeutics

Luisa F. Escobar-Hoyos, Yale School of Medicine, New Haven, Connecticut

6:30 p.m.-6:45 p.m.

Lightning Presentations [CME Eligible]

Xianghui Zou, Zucker School of Medicine, Manhasset, New York (A008)

Yukihito Kuroda, University of Tsukuba, Tsukuba, Japan (A016)

Sabine Naudin, International Agency for Research on Cancer, Lyon, France (A017)

Deepti Mathur, Memorial Sloan Kettering Cancer Center, New York, New York (A060)

Mehrdad Zarei, Case Western Reserve University, Cleveland, Ohio (A105)

Kevin MacPherson, Oregon Health & Science University, Portland, Oregon (A118)

6:45 p.m.-7:30 p.m.

Opening Keynote [CME Eligible]


Novel insights into pancreatic cancer evolution from carcinogenesis to metastasis

Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, New York

7:30 p.m.-9:00 p.m.

Poster Session A / Opening Reception

America South Ballroom



THURSDAY, SEPTEMBER 28

Agu

America Ballroom Foyer


7:00 a.m.–8:00 a.m.

Career Roundtables Session 1

Independence AB Ballroom

Limited to 100 participants; attendance to the Career Roundtables will be on a first-come, first-served basis and with no pre-registration required. Participants will be asked to rotate tables every 20 minutes, providing the opportunity to network and interact with a diverse cadre of expert mentors.

Table Topic and Mentors	Table Topic and Mentors
<p>Conducting Translational Research: How to Get Started Kathleen McAndrews, UT MD Anderson Cancer Center</p>	<p>Collaborating with Industry Erkut Borazanci, Honor Health Research Institute</p>
<p>Choosing a Career Path: Academia vs Industry (1 of 2) Leny Gocheva, Break Through Cancer Paul Kurywchak, Skipper BioMed LLC</p>	<p>Starting Your Lab Jason R. Pitarresi, University of Massachusetts Medical School</p>
<p>Choosing a Career Path: Academia vs Industry (2 of 2) Laura Wood, Johns Hopkins Harmeet Dhani, Biological Dynamics</p>	<p>Getting Tenure Kenneth Olive, Herbert Irving Comprehensive Cancer Center Rushika Perera, University of California San Francisco</p>
<p>How to Get a Paper Published Christine Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center Ben Stanger, University of Pennsylvania Harmony Turk, Executive Editor <i>Cancer Research</i></p>	<p>Balancing Clinical and Research Life Jashodeep Datta, Univ. of Miami Sylvester Comprehensive Cancer Center Cristina Ferrone, Cedars-Sinai Medical Center</p>
<p>How to Write a Grant (1 of 2) Peter Allen, Duke University School of Medicine Mandar Mazumdar, Yale School of Medicine</p>	<p>Entrepreneurship David Ting, Massachusetts General Hospital Manuel Hidalgo, Weil Cornell Medicine</p>
<p>How to Write a Grant (2 of 2) Marina Pasca di Magliano, University of Michigan Medical School Kirsten Bryant, UNC Lineberger Comprehensive Cancer Center</p>	<p>Encouraging Diversity in Your Team Zobeida Cruz-Montserrate, The Ohio State University</p>



**8:15 a.m.–10:00 a.m. Plenary Session 1: Epidemiology and Early Detection
in Honor of Dr. Gloria Petersen [CME Eligible]**

America North and Central Ballroom

Session Chair: Anirban Maitra, The University of Texas MD Anderson Cancer Center, Houston, Texas

- 8:15 a.m.–8:35 a.m. **Genetic epidemiology of pancreatic cancer: Past, present and future**
Alison Klein, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
- 8:35 a.m.–8:40 a.m. Q&A/Discussion
- 8:40 a.m.–8:50 a.m. **Implementation of a real-time AI-guided navigation service for pancreas cancer***
Kristen M. John, Zucker School of Medicine, New Hyde Park, New York
- 8:50 a.m.–8:55 a.m. Q&A/Discussion
- 8:55 a.m.–9:15 a.m. **Molecular detection of pancreatic cancer using methylated DNA markers**
Shounak Majumder, Mayo Clinic, Rochester, Minnesota
- 9:15 a.m.–9:20 a.m. Q&A/Discussion
- 9:20 a.m.–9:30 a.m. **Deep proteomics identifies novel biomarker candidates and molecular pathways of pancreatic cancer-related diabetes***
Lucy Oldfield, University of Liverpool, Liverpool, United Kingdom
- 9:30 a.m.–9:35 a.m. Q&A/Discussion
- 9:35 a.m.–9:55 a.m. **Emerging trends and risk factors for pancreatic cancer in multiethnic populations**
V. Wendy Setiawan, USC Norris Comprehensive Cancer Center, Los Angeles, California
- 9:55 a.m.–10:00 a.m. Q&A/Discussion

10:00 a.m.–10:30 a.m. Break


America Ballroom Foyer

10:30 a.m.–12:15 p.m. Plenary Session 2: Diversity and Disparities [CME Eligible]

America North and Central Ballroom

Session Chair: Nicolette J. Rodriguez, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts

- 10:30 a.m.–10:50 a.m. **Advancing equity in access to PDAC cancer genetics and prevention**
Nicolette J. Rodriguez, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts
- 10:50 a.m.–11:00 a.m. Q&A/Discussion




- 11:00 a.m.-11:10 a.m. **Addressing disparities in the Native American population in Oregon: The development of multi-disciplinary frameworks to study pancreatic ductal adenocarcinoma in Native American communities***
Jared Delaney, Oregon Health & Science University, Portland, Oregon
- 11:10 a.m.- 11:15 a.m. Q&A/Discussion
- 11:15 a.m.-11:35 a.m. **Diversity and disparity in pancreatic cancer care**
Jose Trevino, VCU Massey Cancer Center, Richmond, Virginia
- 11:35 a.m.- 11:45 a.m. Q&A/Discussion
- 11:45 a.m.-12:05 p.m. **Who does the cutting-edge leave behind? Inequities at the frontiers of pancreas cancer care**
Ugwuji N. Maduekwe, Medical College of Wisconsin, Milwaukee, Wisconsin
- 12:05 p.m.- 12:15 p.m. Q&A/Discussion

12:15 p.m.–2:15 p.m. Lunch on Own

2:15 p.m.–4:40 p.m. Plenary Session 3: Clinical Updates [CME Eligible]
America North and Central Ballroom

Session Chair: Talia Golan, Sheba Medical Center, Ramat Gan, Israel

- 2:15 p.m.-2:35 p.m. **Spectrum of response to platinum and PARP inhibitors in HR-deficient pancreatic cancer**
Talia Golan, Sheba Medical Center, Ramat Gan, Israel
- 2:35 p.m.-2:45 p.m. Q&A/Discussion
- 2:45 p.m.-2:55 p.m. **Therapeutic development platform for pancreatic cancer in the UK national health service: Lessons learned and initial results from Precision-Panc***
David K. Chang, University of Glasgow, Glasgow, United Kingdom
- 2:55 p.m.- 3:00 p.m. Q&A/Discussion
- 3:00 p.m.-3:10 p.m. **CheMo4METPANC: Combination Chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in METastatic treatment-naïve PANCreatic adenocarcinoma***
Gulam A. Manji, Columbia University Irving Medical Center/New York Presbyterian, New York, New York
- 3:10 p.m.- 3:15 p.m. Q&A/Discussion
- 3:15 p.m.-3:35 p.m. **Pancreatic cancer clinical updates**
Cristina R. Ferrone, Cedars-Sinai, Los Angeles, California
- 3:35 p.m.- 3:45 p.m. Q&A/Discussion



- 3:45 p.m.-3:55 p.m. **CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Interim efficacy results of the OPTIMIZE-1 phase 1b/2 study***
 Teresa Macarulla, Vall d'Hebrón University Hospital, Barcelona, Spain
- 3:55 p.m.- 4:00 p.m. Q&A/Discussion
- 4:00 p.m.-4:20 p.m. **Clinical updates: Refining the role of radiation in the treatment of pancreas cancer**
 Manisha Palta, Duke Cancer Center, Durham, North Carolina
- 4:20 p.m.- 4:30 p.m. Q&A/Discussion
- 4:30 p.m.-4:40 p.m. **Lightning Presentations**
 Brandon Huffman, Dana-Farber Cancer Institute, Boston, Massachusetts (B005)
 Deepika Bhullar, Sanford Burnham Prebys Medical Discovery Institute, San Diego, California (B013)
 Amanda Decker-Farrell, Columbia University Irving Medical Center, New York, New York (B015)
 Megan Hoffman, Dana-Farber Cancer Institute, Boston, Massachusetts (B016)
 Keilah Garcia Netto, University of New South Wales, Sydney, Australia (B062)

4:40 p.m.-6:40 p.m. **Poster Session B / Reception**
 America South Ballroom

FRIDAY, SEPTEMBER 29


7:00 a.m.-8:00 a.m. **Breakfast**
 America Ballroom Foyer

8:00 a.m.-10:00 a.m. **Plenary Session 4: Systems Biology, Big Data, and Metastasis [CME Eligible]**
 America North and Central Ballroom


Session Chair: Steven Gallinger, Ontario Institute for Cancer Research, Toronto, Canada

- 8:00 a.m.-8:20 a.m. **Developmental and MAPK-responsive programs drive distinct malignant subtypes and dependencies in pancreatic cancer**
 Andrea Califano, Columbia University, New York, New York
- 8:20 a.m.-8:30 a.m. Q&A/Discussion
- 8:30 a.m.-8:40 a.m. **Unravelling the epigenetic landscape of pancreatic cancer: The role of cancer-associated fibroblasts***
 Catarina Pelicano, CRUK University of Cambridge, Cambridge, United Kingdom
- 8:40 a.m.- 8:45 a.m. Q&A/Discussion

*Short talk selected from proffered abstracts
 AACR Special Conference: Pancreatic Cancer
 September 27-30, 2023 | Westin Copley Place | Boston, MA



- 8:45 a.m.-9:05 a.m. **Forecasting pancreatic carcinogenesis through spatial multi-omics**
Elana J. Fertig, Johns Hopkins University, Baltimore, Maryland
- 9:05 a.m.- 9:15 a.m. Q&A/Discussion
- 9:15 a.m.-9:25 a.m. **Spatial mapping of transcriptomic and lineage diversity in metastatic pancreatic cancer***
Jimin Min, UT MD Anderson Cancer Center, Houston, Texas
- 9:25 a.m.- 9:30 a.m. Q&A/Discussion
- 9:30 a.m.-9:50 a.m. **What the surgeon has learned from pancreas cancer genomics, and vice versa**
Steven Gallinger, Ontario Institute for Cancer Research, Toronto, Canada
- 9:50 a.m.- 10:00 a.m. Q&A/Discussion
- 10:00 a.m.–10:30 a.m. Break**
America Ballroom Foyer
- 10:30 a.m.–12:30 p.m. Plenary Session 5: Metabolic Perturbations [CME Eligible]**
America North and Central Ballroom
- Session Chair: Rushika Perera, University of California San Francisco, San Francisco, California*
- 10:30 a.m.-10:50 a.m. **Feeding the flames of pancreatic cancer**
Mandar Muzumdar, Yale School of Medicine, New Haven, Connecticut
- 10:50 a.m.-11:00 a.m. Q&A/Discussion
- 11:00 a.m.-11:10 a.m. **Pancreatic cancer cachexia is mediated by tumor-derived PTHrP***
Jason R. Pitarresi, University of Massachusetts Medical School, Worcester, Massachusetts
- 11:10 a.m.- 11:15 a.m. Q&A/Discussion
- 11:15 a.m.-11:35 a.m. **Identifying and disabling the metabolic engines that fuel pancreatic cancer**
Rushika Perera, University of California San Francisco, San Francisco, California
- 11:35 a.m.- 11:45 a.m. Q&A/Discussion
- 11:45 a.m.-11:55 a.m. **Uridine-to-ribose axis supports glucose-restricted pancreatic cancer***
Zeribe C. Nwosu, University of Michigan, Ann Arbor, Michigan
- 11:55 a.m.- 12:00 p.m. Q&A/Discussion
- 12:00 p.m.-12:20 p.m. **Molecular mechanisms of obesity-associated pancreatic ductal adenocarcinoma**
Zobeida Cruz-Monserrate, The Ohio State University, Columbus, Ohio
- 12:20 p.m.- 12:30 p.m. Q&A/Discussion



12:30 p.m.–2:30 p.m. Lunch on Own


1:00 p.m.–2:00 p.m. Career Roundtables Session 2
 Independence AB Ballroom

Limited to 100 participants; attendance to the Career Roundtables will be on a first-come, first-served basis and with no pre-registration required. Participants will be asked to rotate tables every 20 minutes, providing the opportunity to network and interact with a diverse cadre of expert mentors.

Table Topic and Mentors	Table Topic and Mentors
Conducting Translational Research: How to Get Started Steven Gallinger, Ontario Institute for Cancer Research	Collaborating with Industry Julian Adams, Stand Up To Cancer Timothy Donahue, UCLA David Geffen School of Medicine
Choosing a Career Path: Academia vs Industry (1 of 2) Gargi Basu, EXACT Sciences Corp. Arnav Mehta, MGH/Harvard Medical School	Starting Your Lab Yang Chen, UT MD Anderson Cancer Center William Freed-Pastor, Dana-Farber Cancer Institute
Choosing a Career Path: Academia vs Industry (2 of 2) John Morris, University of North Carolina at Chapel Hill	Getting Tenure Ingunn Stromnes, University of Minnesota Eric Collisson, University of California San Francisco
How to Get a Paper Published Direna Alonso Curbelo, Institute for Research in Biomedicine - IRB Barcelona Anirban Maitra, UT MD Anderson Avital (Tali) Lev, Senior Editor <i>Cancer Discovery</i>	Balancing Clinical and Research Life Filip Bednar, University of Michigan Eileen O'Reilly, Memorial Sloan Kettering Cancer Center
How to Write a Grant (1 of 2) Rosalie Sears, OHSU Howard Crawford, Henry Ford Health System	Entrepreneurship Jen Jen Yeh, University of North Carolina at Chapel Hill
How to Write a Grant (2 of 2) Andy Aguirre, Dana-Farber Cancer Institute John Brody, OHSU	Encouraging Diversity in Your Team Brittany Allen-Petersen, Purdue University Debora Vendramini Costa, Henry Ford Health System

2:30 p.m.–4:40 p.m. Plenary Session 6: RAS, Oncogene Addiction, & Other Targeted Therapies [CME Eligible]
 America North and Central Ballroom

Session Chair: Rosalie C. Sears, Oregon Health & Science University, Portland, Oregon




- 2:30 p.m.-2:50 p.m. **KRAS inhibition and the TME: Two for the price of one**
Ben Z. Stanger, University of Pennsylvania, Philadelphia, Pennsylvania
- 2:50 p.m.-3:00 p.m. Q&A/Discussion
- 3:00 p.m.-3:10 p.m. **KRAS mutant-specific interactions reveal mechanisms in pancreatic cancer tumorigenesis and metabolic function***
G. Aaron Hobbs, Medical University of South Carolina, Charleston, South Carolina
- 3:10 p.m.- 3:15 p.m. Q&A/Discussion
- 3:15 p.m.-3:35 p.m. **Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer**
Ronald A. DePinho, UT MD Anderson Cancer Center, Houston, Texas
- 3:35 p.m.- 3:45 p.m. Q&A/Discussion
- 3:45 p.m.-3:55 p.m. **Targeting CDK7/9 in basal pancreatic cancer***
Sita Kugel, Fred Hutch Cancer Center, Seattle, Washington
- 3:55 p.m.- 4:00 p.m. Q&A/Discussion
- 4:00 p.m.-4:20 p.m. **MYC's role in liver metastatic poor outcome pancreatic ductal adenocarcinoma**
Rosalie C. Sears, Oregon Health & Science University, Portland, Oregon
- 4:20 p.m.- 4:30 p.m. Q&A/Discussion
- 4:30 p.m.-4:40 p.m. **Lightning Presentations**
Peter Yu, NYU Grossman School of Medicine, New York, New York (C054)
Kyle McAndrews, University of Nebraska Medical Center, Omaha, Nebraska (C055)
Johann Gout, Institute for Molecular Oncology and Stem Cell Biology, Ulm, Germany (C061)
Ifeanyichukwu Ogobuiro, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida (C065)

4:40 p.m.-6:40 p.m. Poster Session C / Reception
America South Ballroom

SATURDAY, SEPTEMBER 30

7:00 a.m.-8:00 a.m. Breakfast
America Ballroom Foyer

8:00 a.m.-10:00 a.m. Plenary Session 7: Model Systems [CME Eligible]
America North and Central Ballroom




Session Chair: Jonathan R. Brody, OHSU Knight Cancer Institute, Portland, Oregon

- 8:00 a.m.-8:20 a.m. **Addressing the hallmarks of pancreatic cancer**
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
- 8:20 a.m.-8:30 a.m. Q&A/Discussion
- 8:30 a.m.-8:40 a.m. **Single-cell mapping reveals a common origin for diverse subtypes of pancreatic cancer ***
Nirakar Rajbhandari, University of California San Diego, La Jolla, California
- 8:40 a.m.- 8:45 a.m. Q&A/Discussion
- 8:45 a.m.-9:05 a.m. **Understanding KRAS cancer initiation and progression**
Lukas E. Dow, Weill Cornell Medicine, New York, New York
- 9:05 a.m.- 9:15 a.m. Q&A/Discussion
- 9:15 a.m.-9:25 a.m. **Ex vivo models of pancreatic cancer that recapitulate the metabolic tumor microenvironment identify glycine as a chemoresistance-inducing oncometabolite***
Alexander Muir, University of Chicago, Chicago, Illinois
- 9:25 a.m.- 9:30 a.m. Q&A/Discussion
- 9:30 a.m.-9:50 a.m. **PDAC's response to a stressful environment reveals targets and resistance mechanisms**
Jonathan R. Brody, OHSU Knight Cancer Institute, Portland, Oregon
- 9:50 a.m.- 10:00 a.m. Q&A/Discussion
- 10:00 a.m.–10:15 a.m. Break**
America Ballroom Foyer
- 10:15 a.m.–12:15 p.m. Plenary Session 8: Therapeutic Opportunities in Tumor Stroma and Immune Microenvironments [CME Eligible]**
America North and Central Ballroom

Session Chair: Ingunn M. Stromnes, University of Minnesota, Minneapolis, Minnesota

- 10:15 a.m.-10:35 a.m. **Pancreatic cancer – exceptional survivors to RNA vaccines**
Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, New York
- 10:35 a.m.-10:45 a.m. Q&A/Discussion
- 10:45 a.m.-10:55 a.m. **Adenosine inhibits STING driven anti-tumor immunity in pancreatic cancer***
Alykhan Premji, University of California Los Angeles, Los Angeles, California



11:55 a.m.- 11:00 a.m. Q&A/Discussion

11:00 a.m.-11:20 a.m. **Tumor microbes driving therapies responses**

Florencia McAllister, UT MD Anderson Cancer Center, Houston, Texas

11:20 a.m.- 11:30 a.m. Q&A/Discussion

11:30 a.m.-11:40 a.m. **Neutrophil-intrinsic tumor necrosis factor (TNF) is a novel driver of T-cell and cancer-associated fibroblast (CAF) dysfunction in pancreatic cancer***

Anna Bianchi, University of Miami Miller School of Medicine, Miami, Florida

11:40 a.m.- 11:45 a.m. Q&A/Discussion

11:45 a.m.-12:05 p.m. **Elucidating mechanisms of immunotherapy response in pancreatic cancer**

Ingunn M. Stromnes, University of Minnesota, Minneapolis, Minnesota

12:05 p.m.- 12:15 p.m. Q&A/Discussion

12:15 p.m.-12:20 p.m. Closing Remarks

Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, New York

Anirban Maitra, The University of Texas MD Anderson Cancer Center, Houston, Texas

Rosalie C. Sears, Oregon Health & Science University, Portland, Oregon

Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina